Targeting interleukin-4 and interleukin-13 in the treatment of severe eosinophilic asthma
<p>Asthma is a chronic inflammatory airway disease affecting about 300 million people and responsible for 500,000 deaths annually globally. Eosinophilic asthma is one of the most common phenotypes of asthma. It constitutes about 50% to 60% of all cases of asthma, and it is the most common phen...
I tiakina i:
Kaituhi matua: | Nightingale Syabbalo (Author) |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
Archives of Pulmonology and Respiratory Care - Peertechz Publications,
2023-02-02.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ngā tūemi rite
-
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
mā: Corrado Pelaia, me ētahi atu.
I whakaputaina: (2022) -
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
mā: Pelaia C, me ētahi atu.
I whakaputaina: (2017) -
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
mā: Yuliya Lytvyn, me ētahi atu.
I whakaputaina: (2023) -
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
mā: Giancarlo Marone, me ētahi atu.
I whakaputaina: (2019) -
Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation
mā: L. H. Faccioli, me ētahi atu.
I whakaputaina: (1998)